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Aims Takotsubo cardiomyopathy (TTC) remains a potentially life-threatening disease, which is clinically indistinguishable from
acute myocardial infarction (MI). Today, no established biomarkers are available for the early diagnosis of TTC and dif-
ferentiation fromMI. MicroRNAs (miRNAs/miRs) emerge as promising sensitive and specific biomarkers for cardiovas-
cular disease. Thus, we sought to identify circulating miRNAs suitable for diagnosis of acute TTC and for distinguishing
TTC from acute MI.
Methods
and results
AftermiRNAprofiling, eightmiRNAswere selected for verificationby real-timequantitative reverse transcriptionpolymer-
ase chain reaction in patients with TTC (n ¼ 36), ST-segment elevation acute myocardial infarction (STEMI, n ¼ 27), and
healthy controls (n ¼ 28). We quantitatively confirmed up-regulation of miR-16 and miR-26a in patients with TTC com-
pared with healthy subjects (both, P, 0.001), and up-regulation of miR-16, miR-26a, and let-7f compared with STEMI
patients (P, 0.0001, P, 0.05, and P, 0.05, respectively). Consistent with previous publications, cardiac specific miR-1
and miR-133a were up-regulated in STEMI patients compared with healthy controls (both, P, 0.0001). Moreover, miR-
133a was substantially increased in patients with STEMI compared with TTC (P, 0.05). A unique signature comprising
miR-1, miR-16, miR-26a, and miR-133a differentiated TTC from healthy subjects [area under the curve (AUC) 0.835,
95%CI 0.733–0.937, P, 0.0001] and from STEMI patients (AUC 0.881, 95%CI 0.793–0.968, P, 0.0001). This signature
yielded a sensitivity of 74.19% and a specificity of 78.57% for TTC vs. healthy subjects, and a sensitivity of 96.77% and a spe-
cificity of 70.37% for TTC vs. STEMI patients. Additionally, we noticed a decrease of the endothelin-1 (ET-1)-regulating
miRNA-125a-5p in parallel with a robust increase of ET-1 plasma levels in TTC comparedwith healthy subjects (P, 0.05).
Conclusion The present study for the first time describes a signature of four circulating miRNAs as a robust biomarker to distinguish
TTC from STEMI patients. The significant up-regulation of these stress- and depression-relatedmiRNAs suggests a close
connection of TTCwith neuropsychiatric disorders. Moreover, decreased levels of miRNA125a-5p as well as increased
plasma levels of its target ET-1 are in line with the microvascular spasm hypothesis of the TTC pathomechanism.
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Introduction
Takotsubo cardiomyopathy (TTC) is an increasingly recognized
acute syndrome with symptoms similar to acute myocardial infarc-
tion (MI), including chest pain and electrocardiographic changes,
mostly in the absence of obstructive coronary artery disease.1–5
The syndrome is often triggered by emotional or physical stress
factors and comprises reversiblewall motion abnormalities involving
apical, midventricular, basal or focal segments of the left ventricle.6–8
Even if wall motion abnormalities usually resolve within few days to
weeks and theoverall prognosis is favourable,9–11TTCremains a life-
threatening disease in the acute phase, since 10% of the patients
develop malignant arrhythmia, cardiogenic shock, or ventricular
wall rupture12 with a mortality rate up to 8%.11,13–15 In the acute
phase, TTC is indistinguishable from acute MI with respect to clinical
symptoms, ECG changes, and cardiac biomarkers such as troponin,
creatine kinase (CK), and CK-MB. Although the peak ratio of NT-
proBNP/troponin has been described to distinguish patients with
TTC and acute MI,16 fast and accurate diagnosis on admission
remains challenging, and coronary angiography is still mandatory to
exclude acute MI. Thus, there is a need for sensitive and specific
biomarkers for the early diagnosis of TTC.
MicroRNAs (miRNAs/miRs) are a class of highly conserved, small
(19–25 nucleotides) noncoding post-transcriptional regulators of
diverse cellular processes including proliferation, angiogenesis, differ-
entiation, and apoptosis.17MicroRNAshave recently been considered
as biomarkers in cardiovascular disease,18 i.e. in heart failure,19 stable
coronary artery disease,20 and acute MI.21,22 Thus, we hypothesized
that miRNAs may serve as sensitive and specific biomarkers in TTC
allowing for immediate diagnosis. Therefore, we searched for circulat-
ing miRNAs regulated in the acute course of TTC.
Methods
Study population
Patients from the International Takotsubo Registry (www.takotsubo-
registry.com) contributed from five collaborating centres (Zurich, Hei-
delberg, Gdansk, Lucerne, and Hannover) were included in the present
study if they fulfilled theMayoClinicDiagnosticCriteria forTTC.6 Forcom-
parison, patients with ST-segment elevation acute myocardial infarction
(STEMI) were included, based on the ESC/AHA/ACC guidelines.23,24
Healthy subjects were recruited after coronary angiography if coronary
artery disease and preserved left ventricular ejection fraction were not
present. All groups were age- and gender-matched and presented a
similar cardiovascular risk profile.
Plasma samples were prospectively collected within 24 h after the
onsetof symptoms.Data on clinical presentation, precipitating factors, car-
diovascular risk factors, medications, and demographics were obtained as
well. Full recovery of wall motion abnormalities in TTC patientswas docu-
mentedby follow-upechocardiography. Baselinecharacteristics are shown
in Table 1. The study adhered to the requirements of the local ethics com-
mittee. Written informed consent was obtained from all patients.
Plasma collection and storage
In brief, blood sampleswereobtained fromall patients in the cardiac cath-
eterization laboratory. Blood was drawn into standard tubes containing
1.8 mgof K2EDTApermillilitre of blood (VacutainerTM, BecktonDick-
inson, Franklin Lakes,NJ, USA). Immediate centrifugationwas carried out
for 15 min at 1300 g at room temperature. Supernatant was aspirated,
centrifuged, aliquoted into RNase/DNase-free cryovials, and stored at
–808C until assayed.
RNA isolation and detection
RNAwas isolated from100 mLof plasmawith theMiRNeasy IsolationKit
(Qiagen, Hilden,Germany) according to themanufacturer’s instructions.
Fivemicrolitres of 1 fmol/mL Caenorhabditis elegansmiR-39 (cel_miR-39)
was supplemented as an internal standard before starting the isolation
procedure.25
MicroRNA array and validation
For the screening of differentially regulated miRNAs, five RNA samples
of each group were pooled and miRNA expression was measured
by TaqManw Human MicroRNA Card A and B Array, version 2.0
(Applied Biosystemsw, Foster City, CA, USA) containing probes for a
total of 667 human miRNAs. According to array results and literature,
candidate miRNAs were chosen for further validation with reverse tran-
scription polymerase chain reaction (RT–PCR). Complementary DNA
was synthesized using the Reverse Transcription TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystemsw) according to the man-
ufacturer’s instructions. Quantitative RT–PCR (qRT–PCR) was per-
formed with specific TaqMan miRNA assays (Applied Biosystemsw) for
quantification of miR-1, miR-16, miR-26a, miR-125a-5p, miR-133a,
miR-519d, let-7f, and cel_miR-39. Results were normalized to the
amount of cel_miR-39 as described previously.26Quantitative determin-
ation of miRNAs was calculated using the standard curve method.
Measurement of endothelin-1
Plasma levels of endothelin-1 (ET-1)were determined in 75 mLof plasma
using a commercially available quantitative sandwich enzyme immuno-
assay (QuantikineTM, R&D Systems, Abingdon, UK).
Statistical analysis
Values areexpressedasmean+ SEMormedianwith inter-quartile range
(IQR). Shapiro–Wilk and Kolomogorov–Smirnov tests were used to
test for non-Gaussian distribution. Student’s two-sided t-test or
one-way ANOVA, followed by Bonferroni’s multiple comparison test
as a post hoc analysis, was used for normally distributed values. For vari-
ables without normal distribution, Mann–Whitney U test or Kruskal–
Wallis test was performed. Receiver operating characteristic curves
were analysed to assess specificity and sensitivity of single-plasma
miRNAs and their combination usingmultiple logistic regression analysis.
The optimal diagnostic point of the signature was assessed at cut-off
values with the largest Youden’s index (sensitivity + specificity2 1).
To investigate the clinical impact of our signature miRNAs, we have
chosen the likelihood ratio (LR) in addition to classical test para-
meters—sensitivity and specificity, because it combines information of
both.Odds ratio per standard deviationwas calculated by logistic regres-
sion analysis.
Statistical analyses were performed using IBM SPSS Statistics 20 (SPSS,
Inc., Chicago, IL, USA), SAS 9.3 (SAS Institute, Inc., USA), and GraphPad
Prism 5. The following values were considered significant: P, 0.05 (*),
P, 0.01 (**), and P, 0.001 (***).
Results
MicroRNA array
MicroRNA array screening revealed let-7f, miR-22, and miR-519d as
the most significantly up-regulated miRNAs in the TTC group
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compared with healthy controls. Moreover, we detected a dysregu-
lation of miR-16 and miR-26a, recently described as stress- and
depression-relatedmiRNAs. In addition, miR-125a-5p, which is a po-
tential regulator of ET-1 expression in vascular endothelial cells, was
down-regulated in the miRNA array (Figure 1).
All above-mentioned miRNAs were considered for further valid-
ation together with miR-1 and miR-133a, two miRNAs well-known
to be increased after MI.21,22,27
Validation of microRNAs
Using cel-miR-39 as normalization control, we notified a significant
induction of miR-16 and miR-26a, both previously described in
stress response,28,29 in TTCpatients comparedwith healthy controls
(both, P, 0.001) and STEMI patients (P, 0.0001 and P, 0.05, re-
spectively; Figure 2). In addition, let-7fwas significantly up-regulated in
TTC patients compared with STEMI patients (P, 0.05, Figure 2).
There was no significant difference in miR-22 expression between
groups (Figure 2), and miR-519d could not be detected in several
samples; therefore, both were omitted for further analysis (Figure 2).
miR-1 and miR-133a, both previously described to be associated with
MI, were up-regulated in STEMI patients comparedwith healthy controls
(both,P, 0.0001), confirmingpreviouslypublisheddata.21,22,27miR-133a
was substantially increased in patients with STEMI compared with those
with TTC (P, 0.05). Interestingly, both miR-1 and miR-133a were also
significantly up-regulated in patients with TTC compared with healthy
controls (P, 0.001 and P, 0.05, respectively). However, absolute ex-
pression levels did not reach values of STEMI samples.
MicroRNA signature for the identification
of patients with takotsubo cardiomyopathy
miR-16, miR-26a,miR-1, andmiR-133awere significantly up-regulated
in TTCpatients comparedwith healthy controls (Figure 2). However,
the area under the curve (AUC) was ≤0.779 for each single-miRNA
to predict TTC (Figure 3, Table 2). Combinations of two miRNAs
slightly increased the AUC to 0.792, whereas the combination out
of three miRNAs pushed the AUC in TTC to healthy subjects to a
maximum of 0.824 by OR per SD of 4.221 (95% CI 1.956–9.109)
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Table 1 Baseline characteristics
Variable TTC (n 5 36) STEMI (n 5 27) Healthy (n 5 28) P-value
Age (years), mean (+SD) 68.7 (+12.0) 67.1 (+7.4) 63.7 (+5.1) 0.093
Female gender, n (%) 33 (92) 23 (85) 24 (86) 0.680
BMI, kg/m2 23.4 (+4.5) 27.6 (+6.9) 25.1 (+4.5) 0.020
LVEF (%), mean (+SD) 40.7 (+10.3) 47.1 (+11.3) 60.5 (+3.1) ,0.001
Cardiovascular risk factors
Arterial hypertension, n (%) 20 (56) 17 (63) 15 (54) 0.648
Hyperlipidaemia, n (%) 7 (19) 12 (44) 10 (36) 0.077
Smoking, n (%) 10 (28) 9 (33) 1 (4) 0.007
Diabetes mellitus, n (%) 3 (8) 3 (11) 5 (18 0.519
Positive family historya, n (%) 11 (31) 10 (37) 6 (21) 0.292
Cardiovascular history
Non-obstructive CADb 6 (17) 0 0
Obstructive CADc, n (%) 3 (8) 27 (100) 0 ,0.001
Re-animation, n (%) 3 (8) 6 (22) 0 0.155
Laboratory values on admission
NT-proBNP (ng/L), median (IQR) 449.0 (172.0–3065.0) 396.4 (157.9–1479.8) 145.0 (115.0–194.0) 0.110
Troponin (mg/L), median (IQR) 0.3 (0.1–0.7) – – –
hsTroponin (pg/mL), median (IQR) 257.0 (74.5–267.0) 350.0 (43.3–1545.0) – 0.361
CK (U/L), median (IQR) 149.0 (110.5–197.3) 491.0 (208.3–1582.0) 107.0 (73.5–157.0) 0.002
CKMB (U/L), median (IQR) 14.0 (6.83–26.0) 132.0 (19.5–255.0) 14.0 (11.3–17.8) ,0.001
Medication on admission
ACE-inhibitor or ARB, n (%) 11 (31) 4 (15) 13 (46) 0.071
Beta-blocker, n (%) 11 (31) 1 (4) 11 (39) 0.011
aDefined as a myocardial infarction in direct blood relatives of the patient (male ,55 years; female ,65 years).
bAtherosclerosis and lesions ,50%.
cAt least one stenosis of ≥50%.
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BMI, body mass index; CAD, coronary artery disease; CK, creatine kinase; CKMB, creatine kinase
MB-isoenzyme; LVEF, left ventricle ejection fraction;NT-proBNP,N-terminal pro-hormonebrain natriuretic peptide; STEMI, ST-segment elevation acutemyocardial infarction; TTC,
takotsubo cardiomyopathy; IQR, inter-quartile range.
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and in TTC to STEMI to a maximum of 0.879 by OR per SD of 8.739
(95% CI 2.271–27.559).
Notably, the combination of all fourmiRNAs resulted in a robustly
increased AUC, leading to a signature for the prediction of TTC
(Figure 4, Table 2). Multiple logistic regression analysis revealed an
AUC of 0.835 (95% CI 0.733–0.937) by OR per SD of 2.457 (95%
CI 1.440–4.192) when comparing the signature of TTC to healthy
subjects and 0.881 (95% CI 0.793–0.968) by OR per SD of 5.495
(95% CI 2.391–12.629) comparing the combination of miRNAs of
TTC with STEMI patients.
In contrast to the independent cut-off values between TTC and
healthy subjects for every miRNA (.0.872 for miR-16, .0.415 for
miR-26a, .4.359 for miR-1, and .0.438 for miR-133a), a global
cut-off value of .0.511 for all signature miRNAs pushed the
Figure1 MicroRNA array profiling in patients with takotsubo cardiomyopathy comparedwith healthy subjects. Red colour indicatesmicroRNA
candidates considered for the real-time quantitative reverse transcription polymerase chain reaction validation.miR-1was not detectable in healthy
subjects and, therefore, not presented here.
Figure 2 Comparative analysis of expression levels for selected microRNA candidates for takotsubo cardiomyopathy, ST-segment elevation
acute myocardial infarction, and healthy controls; *P, 0.05, **P, 0.001, ***P, 0.0001.
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diagnostic power to a 74.19% sensitivity and a 78.57% specificity for
the differentiation. Accordingly, despite the single-miRNA cut-off
values between TTC and STEMI (.0.866 for miR-16, .0.684 for
miR-26a, ,13.410 for miR-1, and ,2.473 for miR-133a), a global
cut-off value of .0.385 for all signature miRNAs increased the diag-
nostic power to a96.77%sensitivity and a70.37%specificity (Table 2).
miRNA-125a-5p and endothelin-1
expression
Validation of miR-125a-5p revealed a strong although not formally
significant down-regulation in patients with TTC compared with
healthy subjects. Levels of ET-1, a commonly known target of
miR-125a-5p, were significantly increased in patients with TTC, sug-
gesting a potential role of the miR-125a-5p-ET-1 axis in TTC patho-
genesis (Figure 5).
Discussion
This study for the first time reports (i) a novel signature of four circu-
lating miRNAs allowing to distinguish TTC from STEMI patients in an
acute setting; (ii) that stress- and depression-related miRNAs are
up-regulated in this setting in line with known triggers of TTC; and
(iii) that ET-1, a possible mediator of myocardial ischaemia in TTC,
is produced at increased amounts in parallel to an down-regulation
of the ET-1-regulating miRNA125a-5p. Thus, this study provides
novel insights into both the diagnosis and pathogenesis of TTC.
Biomarkers remain an essential tool in daily clinical practice for
diagnosis, risk prediction, and therapeutic decision-making, particu-
larly in the emergency setting. Biomarkers also contribute to the
understanding of the pathomechanisms of a given disease. Takotsubo
cardiomyopathy essentially mimics acute MI in clinical presentation
and a profile of common cardiac necrosis biomarkers that hampers
a rapid diagnosis.16 Today, no biomarker exists to differentiate
TTC from MI in the acute phase. Sampling of circulating plasma
miRNAs represents a potential new approach for non-invasive and
rapid diagnostic screening using polymerase chain reaction.18 In the
present study, we identified for the first time a unique signature of
differentially regulated miRNAs distinguishing patients with TTC
from those with STEMI (sensitivity 96.77%, specificity 70.37%) and
healthy subjects (sensitivity 74.19%, specificity 78.57%). The predict-
ive accuracy of ourmiRNA signature distinguishing TTC from STEMI
patients and healthy subjects was similar to those recently published
to differentiate acute MI from non-MI patients.22,30
MicroRNAs in acute myocardial infarction
In line with the current literature, our results confirm that miRNAs
are differentially regulated in patients with acute MI. Serum levels
of miR-1, miR-133a/b, miR-208a/b, and miR-499–5p are altered in
patients with acute MI.21,22,27,31 The most commonly reported
miRNAs for the identification of acute MI are miR-1 and miR-133a.
Interestingly, serum levels of miR-1, -133a, and -133b reach peak
Figure 3 ROC curve analysis for single microRNAs (A: miR-16; B: miR-26a; C: miR-1; D: miR-133a) and combinations (E: miR-16+miR-26a;
F: miR-1+miR-133a;G: miR-16+miR-26a+miR-1;H: miR-16+miR-26a+miR-133a) to discriminate takotsubo cardiomyopathy from healthy con-
trols and ST-segment elevation acute myocardial infarction patients.
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Table 2 Receiver operating characteristic curves
AUC 95% CI P-value OR per SD 95% CI Cut off Sensitivity
(%)
95% CI Specificity
(%)
95% CI LR1 LR2
TTC vs. healthy
miR-16 0.762 0.643–0.881 ,0.001 3.093 1.594–6.002 .0.872 68.75 49.99–83.88 75.00 55.13–89.31 2.75 0.42
miR-26a 0.725 0.589–0.860 ,0.01 4.812 2.272–10.192 .0.415 61.29 42.19–78.15 89.29 71.77–97.73 5.72 0.43
miR-1 0.779 0.658–0.900 ,0.001 3.314 1.656–6.632 .4.359 81.25 63.56–92.79 75.00 55.13–89.31 3.25 0.25
miR-133a 0.757 0.629–0.884 ,0.001 2.379 1.324–4.276 .0.438 68.75 49.99–83.88 78.57 59.05–91.70 3.21 0.40
miR-16+miR-26a 0.773 0.655–0.892 ,0.001 3.098 1.581–6.071 .0.460 58.06 39.08–75.45 89.29 71.77–97.73 5.42 0.47
miR-1+miR-133a 0.792 0.673–0.911 ,0.001 3.100 1.623–5.921 .0.020 81.25 63.56–92.79 78.57 59.05–91.70 3.79 0.24
miR-16+miR-26a+miR-1 0.824 0.718–0.929 ,0.0001 4.221 1.956–9.109 .20.350 83.87 66.27–94.55 71.43 51.33–86.78 2.94 0.23
miR-16+miR-26a+miR-133a 0.805 0.695–0.916 ,0.0001 3.339 1.694–6.579 .0.026 77.42 58.90–90.41 71.43 51.33–86.78 2.71 0.32
Signaturea 0.835 0.733–0.937 ,0.0001 2.457 1.440–4.192 .0.511 74.19 55.39–88.14 78.57 59.05–91.70 3.46 0.33
TTC vs. STEMI
miR-16 0.777 0.660–0.893 ,0.001 3.524 1.666–7.452 .0.866 68.75 49.99–83.88 81.48 61.92–93.70 3.71 0.38
miR-26a 0.700 0.561–0.839 ,0.01 3.824 1.887–7.753 .0.684 48.39 30.15–66.94 96.30 81.03–99.91 13.1 0.54
miR-1 0.644 0.496–0.790 0.06 0.896 0.531–1.511 , 13.41 75.0 56.59–88.54 59.26 38.80–77.61 1.84 0.42
miR-133a 0.751 0.615–0.887 ,0.001 0.358 0.189–0.679 ,2.473 90.63 74.98–98.02 62.96 42.37–80.60 2.45 0.15
miR-16+miR-26a 0.786 0.670–0.902 ,0.001 3.564 1.679–7.562 .0.277 70.97 51.96–85.78 81.48 61.92–93.70 3.83 0.36
miR-1+miR-133a 0.770 0.637–0.903 ,0.001 3.552 1.868–6.757 .0.186 84.38 67.21–94.72 70.37 49.82%–86.25 2.85 0.22
miR-16+miR-26a+miR-1 0.863 0.772–0.953 ,0.0001 5.104 2.188–11.908 .20.948 96.77 83.30–99.92 59.26 38.80–77.61 2.38 0.05
miR-16+miR-26a+miR-133a 0.879 0.792–0.967 ,0.0001 8.739 2.771–27.559 .20.381 93.55 78.58–99.21 70.37 49.82–86.25 3.16 0.09
Signaturea 0.881 0.793–0.968 ,0.0001 5.495 2.391–12.629 .0.385 96.77 83.30–99.92 70.37 49.82–86.25 3.27 0.05
AUC, area under the curve; CI, confidence interval; LR+, positive likelihood ratio; LR2, negative likelihood ratio; miR, microRNA;OR, odds ratio per standard deviation; STEMI, ST-segment elevation acute myocardial infarction; TTC, takotsubo
cardiomyopathy.
amiR-16+miR-26a+miR-1+miR-133a.
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concentrations before troponin during acute MI in humans.21 More-
over,miR-1 andmiR-133ahave recentlybeen shown tobe also slight-
ly increased in patients with unstable angina and TTC.32 This result is
consistentwith ourobservation thatmiR-1 andmiR-133a expression
is strongly up-regulated in STEMI patients and only weakly increased
in TTC patients.
Ofnote, inour study,miR-1 andmiR-133a strengthenour signature
to distinguish patients with TTC and STEMI. Therefore, miR-1 and
miR-133a are obviously not general markers of acute cardiac disease,
but differentially respond depending on the underlying diagnosis.
MicroRNAs and neurological and
psychiatric insights of stress
A particularly interesting finding was that—in addition to the
related miRNAs miR-1 and miR-133a21,22,27—this unique miRNA
signature included miR-16 and miR-26a, both known as stress-
and depression-related miRNAs that appear to play a key role in
the stress response to sudden environmental changes.28,29,33 –35
The fact that this psychological stress response is potentially de-
tectable in peripheral blood has already been described.29 Indeed,
miR-16 is altered in healthy Japanese medical students after an
acute stress stimulus29 and is, therefore, thought to be part of a
general stress response in healthy subjects.29 Furthermore, miR-
26a is overexpressed in brain tissue of stressed mice.28 Thus,
these findings are well in line with the known high incidence of psy-
chosocial or mental triggers preceding the TTC event and could in-
dicate potential psychiatric co-morbidities in these patients.36,37
Frequent episodes of depression and anxiety have been implicated
as potential risk factors predisposing to TTC.38
The power of the signature
Our receiver operating characteristic curves (Table 2) revealed that
the power of diagnostic test for TTC was associated with the
number of linked miRNAs in our signature. Although already one
miRNA could discriminate to AUC of 0.779 between the different
groups, this approach failed in appropriate LR and OR per SD.
Every additionally added miRNA prooved to increase AUC as also
LR and OR per SD. Only the combination of four miRNAs
managed to deliver an increased discrimination (AUC 0.881) with a
high positive LR in accordancewith a low negative LR in combination
with an appropriateOR per SDwith a narrow 95%CI (Table 2, signa-
ture values). This increased diagnostic power is provided by a global
cut-off value for all signature miRNAs, combining the advantages of
different miRNA expression values and physiological regulation of
certain miRNAs. Hence, we are able not only to show one biomark-
er—in terms of miRNA regulation, we are now able to show a
network of associated regulation in TTC. In all other set-ups (one,
two, or three combinedmiRNAs),we recognized either highpositive
LR linked with high negative LR or otherwise. Additionally, the OR
per SD either failed in its value or in its appropriate narrow 95% CI
when compared with our signature.
Microvascular vasoconstriction and
takotsubo cardiomyopathy
The exact aetiology of TTC is still unknown; however, numerous po-
tential mechanisms have been proposed.39 Although exaggerated
sympathetic stimulation and alterations of the coronary microcircu-
lation have been described, no causal relationship has been demon-
strated so far.40
Endothelin-1 represents one of the most potent vasoconstrictors
being 100 times more potent than norepinephrine.41–43 This vaso-
constriction is induced via an ultimate acceleration of calcium influx
through voltage-dependent calcium channels. High levels of ET-1
after MI are associated with microvascular obstruction and lower
myocardial salvage index.44 miR-125a-5p inhibits ET-1 expression
in vascular endothelial cells and targets the regions within the
3′-UTR for the transcript for prepro-ET-1, which is highly conserved
Figure 5 Results of the quantitative reverse transcription poly-
merase chain reaction of the miR-125a-5p expression (A) and
endothelin-1 assay (B) in takotsubo cardiomyopathy, ST-segment
elevation acute myocardial infarction and healthy subjects;
*P, 0.05, ***P, 0.0001.
Figure 4 ROC curve analysis for the combination of four micro-
RNAs resulting in enhanced specificity and sensitivity to distinguish
takotsubo cardiomyopathy form healthy subjects (74.2, 78.6%,
respectively) and ST-segment elevation acutemyocardial infarction
controls (96.8, 70.4%, respectively).
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in humans. Therefore, miR-125a-5p may play an essential role as a
novel regulator of vasomotor homeostasis.45 Since we have shown
a tendency towards down-regulation of miR-125a-5p expression in
TTCpatients comparedwith healthy subjects,we subsequentlymea-
sured ET-1. Notably, ET-1 was significantly increased in plasma
samples of patients with TTC. Therefore, a potential role of ET-1
as a mediator of microvascular spasm in TTC can be speculated.
The high levels of ET-1 in STEMI patients may be explained by the
presence of no-reflow46 or reperfusion of ischaemic myocardium.47
The following limitations have to be acknowledged: first, the clin-
ical applicability of the presented results can be limited by the time
required for the determination of signature, the cost of assessment,
and the difficulty to have appropriate laboratory facilities in small
centres. However, on the opposite, the identification of distinct bio-
marker signatures could represent a possible perspective advance-
ment to aid and exclude for other possible player of differential
diagnosis, i.e. acute myocarditis. Furthermore, currently, novel faster
approaches for the quantification of circulating miRNAs, e.g. by high-
performance liquid chromatography, are under development that
will likely lead to a fast detection system in the future.
We demonstrate for the first time a unique signature of circulating
miRNAs to differentiate TTC from STEMI patients. However, these
results need to be confirmed in a large patient cohort to exclude po-
tential bias. Therefore, further investigations should be obtained to
affirm the performance of the signature proposed here.
Conclusion
Here,we, for thefirst time, describe a signatureof circulatingmiRNAs
for sensitive and specific identification of TTC in the acute phase. This
signature may hold great promise to become an important diagnostic
tool for the immediate diagnosis of TTC. The significant up-regulation
of stress- and depression-related miRNAs suggests a role of central
and/or peripheral nervous system in TTC. Furthermore, our findings
suggest that ET-1 may play a role in the pathomechanism of TTC.
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